Minerva Neurosciences Inc
NASDAQ:NERV
Intrinsic Value
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system d... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of NERV.
Minerva Neurosciences Inc's market capitalization is 17m USD.
NERV stock price is 2.43 USD.
NERV.
NERV. Open DCF Valuation
NERV. Open Relative Valuation
NERV has upside potential of 362% compared to the average analyst price target.
Open Wall St Estimates
NERV has negative Operating Income for the last twelve months.
NERV has negative Net Income for the last twelve months.
NERV's ROE (Return on Equity) has significantly increased in the last 3 years from 17% to 124%.
NERV's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 22% to -144%.
NERV's long-term liabilties (85m USD) exceed its long-term assets (57m USD).
NERV's ROE (Return on Equity) for the past 12 months is very high and is equal to 124%.
NERV's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -144%.
NERV has negative Free Cash Flow for the last twelve months.
NERV has negative three-year average ROE (Return on Equity): -20%. The company is not efficient at transforming stockholders' equity into net income.
NERV has negative three-year average ROIC (Return on Invested Capital): -128%. The company is not efficient at using invested capital to generate operating income.
NERV's short-term assets (42m USD) exceed its short-term liabilties (3m USD).
NERV's D/E (Debt to Equity) is very low and is equal to 0.
NERV's Altman Z-Score is very low and is equal to -10.85.
Fundamental Analysis
Minerva Neurosciences Inc
Balance Sheet Decomposition
Minerva Neurosciences Inc
| Current Assets | 42m |
| Cash & Short-Term Investments | 40.9m |
| Other Current Assets | 1.1m |
| Non-Current Assets | 14.9m |
| PP&E | 10.9k |
| Intangibles | 14.9m |
| Current Liabilities | 3.3m |
| Accounts Payable | 1.8m |
| Accrued Liabilities | 1.5m |
| Non-Current Liabilities | 82m |
| Other Non-Current Liabilities | 82m |
Earnings Waterfall
Minerva Neurosciences Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-23.1m
USD
|
|
Operating Income
|
-23.1m
USD
|
|
Other Expenses
|
-6.9m
USD
|
|
Net Income
|
-30m
USD
|
Free Cash Flow Analysis
Minerva Neurosciences Inc
NERV Profitability Score
Profitability Due Diligence
Minerva Neurosciences Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Minerva Neurosciences Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
NERV Solvency Score
Solvency Due Diligence
Minerva Neurosciences Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Minerva Neurosciences Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NERV Price Targets Summary
Minerva Neurosciences Inc
According to Wall Street analysts, the average 1-year price target for
NERV
is 11.22 USD
with a low forecast of 11.11 USD and a high forecast of 11.55 USD.
Ownership
NERV Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
NERV Price
Minerva Neurosciences Inc
| Average Annual Return | -52.16% |
| Standard Deviation of Annual Returns | 36.25% |
| Max Drawdown | -99% |
| Market Capitalization | 17m USD |
| Shares Outstanding | 6 993 410 |
| Percentage of Shares Shorted | 0.99% |
Company Profile
Minerva Neurosciences Inc
Country
Industry
Market Cap
Dividend Yield
Description
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2014-06-25. The firm is focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The firm's lead product candidates are roluperidone (MIN-101), seltorexant and MIN-301. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and α adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The firm is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. The firm is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders.
You don't have any saved screeners yet
